![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 16, 2021
In an annual evaluation, 30 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 16, 2021
This phase II randomized controlled trial is evaluating the effect of adding hydroxychloroquine to treatment with dabrafenib and trametinib in patients with advanced BRAF mutant melanoma
November 16, 2021
A Standing Main Member of ECOG-ACRIN since 1996
November 16, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
October 19, 2021
A focus on the Fall 2021 ECOG-ACRIN Group Meeting; remembering two major leaders in oncology; studying smoking cessation in patients with cancer
October 19, 2021
Though we had hoped to meet in person this fall, the pandemic has kept us on our toes—and in front of our screens.
October 19, 2021
Eight early-career investigators will present their work; two will be selected to receive awards of distinction
October 19, 2021
In September, the field of immunotherapy lost one of its pioneers
October 19, 2021
In September, the field of oncology lost a worldwide ovarian therapeutics leader and unparalleled mentor to generations
October 19, 2021
This phase II randomized controlled trial is comparing the effectiveness of two different approaches to help recently diagnosed patients with cancer become smoke-free
October 19, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
September 30, 2021
A focus on leukemia trials; an update regarding advanced practice providers; two important topics related to patient communication